Douglas Michael Garis bought $632K of Claritev (CTEV)
Executed May 12 2025, disclosed May 13 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 13 2025), the stock returned +76.4% (delay-adjusted); from the execution session (May 12 2025), +66.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Douglas Michael Garis (EVP&CFO) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in Claritev Corporation (CTEV). Across 2 priced purchase filings, the average 21-session return was +35.1% from execution and +43.2% from disclosure (delay-adjusted; derived). The largest single filing was $632K of CTEV (28,749 sh across 2 lots, as filed), executed May 12 2025.
Healthcare · Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, a…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→8,238 sh × $19.62
Exec Mar 7 2025
Filed Mar 10 2025 · 5:30 PM ET